Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - ...

Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned ...

On July 22, 2025, the US Food and Drug Administration (FDA) started accepting applications to participate in the Commissioner’s National ...

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

The US Securities and Exchange Commission (SEC) has approved the conversion of Bitwise 10 Crypto Index into an ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...

The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients ...

The FDA recently unveiled a new national priority voucher program that would seek to trade faster drug approvals for lower ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

The top securities regulator in the US is pausing Bitwise's plan to convert its Bitwise 10 Crypto Index Fund (BITW) into a ...